11 August, 2023
2023 SNO/ASCO CNS Cancer Conference
A Randomized, Controlled Trial Of Berbubicin, A Novel Topoisomerase II Inhibitor, After First-Line Therapy For Glioblastoma Multiforme (GBM): Updated Results
By: Z. Muzyczenko (1), S. Silberman (1), S. Hsu (2), D. Picker (1) (1) CNS Pharmaceuticals, Houston, TX, (2) Memorial Hermann Texas Medical Center, Houston, TX,
Berubicin (Recurrent GBM)